W38--Epidemiology & Management of Infection in CF

Chair(s)

• 

  Joy Gibson, MD, PhD (she/her/hers)

  Children's Hospital Los Angeles
• 

  Bradley Quon

  Medicine
  Centre for Heart Lung Innovation, University of British Columbia, Vancouver, BC, Canada

This session will highlight novel approaches to treatment of challenging pathogens in cystic fibrosis (CF), particularly Mycobacterium abscessus, Pseudomonas, and Stenotrophomonas. These bacteria often persist despite aggressive antimicrobial therapy and can cause significant decline in lung function. During this session, we will cover novel alternative treatment options, new approaches to predicting treatment response, and the interplay between pathogens in the CF microbiome. We will also hear updates on the clinical management and treatment duration for pulmonary exacerbations.

Presentations:

• 10:15 AM – 12:15 PM ET

  W38.1- Impact of the STOP2 trial on PEx treatment duration at CF Centers across the US
  

  Speaker: Sonya L. Heltshe, PhD (she/her/hers) – University of Washington School of Medicine
• 10:15 AM – 12:15 PM ET

  W38.2- Mycobacterium Abscessus Drug Tolerance Assessments Reveal Clinical Outcomes.
  

  Speaker: Lucas Boeck, MD – University of Basel
• 10:15 AM – 12:15 PM ET

  W38.3- Antibiotics used to treat Pseudomonas infections may enhance Mycobacterium abscessus persistence in the CF lung
  

  Speaker: Jodi Corley, PhD (she/her/hers) – National Jewish Health
• 10:15 AM – 12:15 PM ET

  W38.4- Safety and efficacy of nebulized phage in CF patients with chronic Pseudomonas aeruginosa pulmonary infection: A phase 1b/2a randomized, double-blind, placebo-controlled, multicenter study
  

  Speaker: Urania Rappo, MD – BiomX Inc
• 10:15 AM – 12:15 PM ET

  W38.5- Medium chain fatty acids improve bacteriophage killing of Stenotrophomonas maltophilia
  

  Speaker: Sage J. B. Dunham, PhD – UC Irvine